Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer.
about
Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809).Inducible expression of cancer-testis antigens in human prostate cancer.PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine ImmunizationImmunotherapy for prostate cancer: False promises or true hope?Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination.Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses.Therapeutic Cancer Vaccines: How Much Closer Are We?Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).DNA vaccines for prostate cancer.Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine.Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer.Trial watch: DNA-based vaccines for oncological indicationsTherapeutic Vaccines for Genitourinary Malignancies
P2860
Q36256563-C9193518-4B89-481B-BD19-E9765AD29E4EQ37686238-D2640048-BC6A-4BF6-983F-D5A38F69F886Q38867768-D352EE2E-1A03-4666-BEE3-7066554E7284Q38959645-F830F012-930A-4C76-B720-2E879068DAE5Q39093352-52E6BD42-4821-49B2-AE58-D9E4107FFFC4Q41041538-5FA2A02F-C816-40E9-AF62-5170CEA02FF1Q41869616-05A3F8AB-CF5B-448B-8704-3F1A2ACD8724Q47235984-2FCA2E4B-F76B-430F-BBB6-D96F7D44ED12Q48316638-405DE609-63F8-4A61-8325-BBA3F8646473Q51142505-D5B3E4A2-DA9C-41DD-AACD-5013966DDFB2Q53702329-24C1DA43-E13A-43D5-8305-3C1C3D04CD15Q55263045-9583A836-8E36-46CA-8CC3-40CCFD535424Q56893452-E96A8458-82C4-489F-AE03-20AB4807533FQ58787586-0870C8B0-94AB-4951-84F1-03E5B017489D
P2860
Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Real-time immune monitoring to ...... ion-resistant prostate cancer.
@en
Real-time immune monitoring to ...... ion-resistant prostate cancer.
@nl
type
label
Real-time immune monitoring to ...... ion-resistant prostate cancer.
@en
Real-time immune monitoring to ...... ion-resistant prostate cancer.
@nl
prefLabel
Real-time immune monitoring to ...... ion-resistant prostate cancer.
@en
Real-time immune monitoring to ...... ion-resistant prostate cancer.
@nl
P2093
P2860
P1476
Real-time immune monitoring to ...... ion-resistant prostate cancer.
@en
P2093
Brian M Olson
Douglas G McNeel
Eric Bradley
Isabel Pohlkamp
Jens C Eickhoff
Jordan T Becker
Laura E Johnson
Mary Jane Staab
P2860
P304
P356
10.1158/1078-0432.CCR-14-0169
P407
P577
2014-05-21T00:00:00Z